Ponatinib‐induced neutrophilic panniculitis

descriptionPublicationkeyboard_double_arrow_right Article 08 Apr 2014 English Publisher:WileyJournal:Journal of Cutaneous Pathology, volume 41, pages 597-601 (issn: 0303-6987, eissn: 1600-0560,

Copyright policy )

Authors: May, Zhang; Khaled M, Hassan; Amy, Musiek; Ilana S, Rosman;

doi: 10.1111/cup.12326

pmid: 24602068

Ponatinib‐induced neutrophilic panniculitis

- Summary
- Subjects
- Metrics

Abstract

Ponatinib is a bcr‐abl tyrosine‐kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome‐positive acute lymphoblastic leukemia that express bcr‐abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.

Related Organizations

Washington University in St. Louis
United States
University of Mary
United States

Keywords

Pyridazines, Panniculitis, Neutrophils, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Imidazoles, Humans, Female, Middle Aged, Protein Kinase Inhibitors

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	17
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%